血液透析滤过预防透析相关淀粉样变的Meta分析  

Meta-analysis on hemodiafiltration to prevent dialysis-related amyloidosis

作　　者：郑晓勇[1] 魏日胞[2] 汤力[2] 

机构地区：[1]空军总医院风湿肾病科,100142 [2]解放军总医院肾科

出　　处：《中华临床医师杂志（电子版）》2011年第8期2282-2285,共4页Chinese Journal of Clinicians(Electronic Edition)

基　　金：国家科技重大专项(2010ZX9102-204);国家自然科学基金(81072914);全军医药卫生科研基金课题(06MA265);军队中医药专项课题(10ZYZ255)

摘　　要：目的评价长期血液透析滤过治疗对早期预防透析相关淀粉样变的有效性。方法计算机检索PubMed、EMBASE、CochraneLibrary、CBM、CNKI、VIP等数据库发表的有关长期血液透析滤过清除β2微球蛋白的随机对照试验,2名评价员对纳入文献进行质量评价和数据提取,用RevMan5.0软件统计分析。结果共纳入4篇随机对照试验共计158例患者,Meta分析结果显示:长期血液透析滤过治疗能显著清除血β2微球蛋白(MD-6.99,95%CI:-8.41～-5.57;Z=9.66,P<0.00001)。结论长期血液透析滤过能显著清除血β2微球蛋白,有助于早期预防透析相关淀粉样变的发生。Objective To evaluate the effectiveness of long-term hemodiafiltration on the prevention of dialysis-related amyloidosis.Methods We searched MEDLINE,EMBASE,Cochrane Library,CBM,CNKI,VIP and other databases published on the long-term hemofiltration with β2-microglobulin clearance randomized controlled trials,Authors of included studies were contacted,reference lists of identified RCTs and relevant narrative reviews were screened.One author independently assessed trial quality and extracted data.Statistical analyses were performed using the random effects model and the results expressed as mean difference(MD)for continuous data with 95% confidence intervals(CI).Heterogeneity was measured using the Chi-square(χ2)and I2 statistic.Statistical analyses were performed using software RevMan 5.0.Results Four studies(158 patients)were included.Long-term hemodiafiltration can effectively removal with serum β2-microglobulin(MD-6.99,95% CI-8.41,-5.57;Z=9.66,P<0.00001).Conclusions Long-term hemodiafiltration can effectively removal with serum β2-microglobulin and be helpful to early prevention of dialysis-related amyloidosis.

关 键 词：血液透析滤过 Β2微球蛋白 META分析 透析相关淀粉样变性 

分 类 号：R459.5[医药卫生—治疗学]